US 12,071,438 B2
Crystal forms of an ALK2 inhibitor
Sarah Bethune, Longmont, CO (US); Krista Diaz, Longmont, CO (US); and Catherine A. Evans, Somerville, MA (US)
Assigned to Keros Therapeutics, Inc., Lexington, MA (US)
Filed by Keros Therapeutics, Inc., Lexington, MA (US)
Filed on Apr. 23, 2021, as Appl. No. 17/238,986.
Application 17/238,986 is a continuation of application No. PCT/US2019/058062, filed on Oct. 25, 2019.
Claims priority of provisional application 62/751,255, filed on Oct. 26, 2018.
Prior Publication US 2021/0238185 A1, Aug. 5, 2021
Int. Cl. C07C 55/10 (2006.01); A61P 19/02 (2006.01); A61P 19/08 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); A61P 37/00 (2006.01); A61P 43/00 (2006.01); C07D 487/04 (2006.01)
CPC C07D 487/04 (2013.01) [C07B 2200/13 (2013.01)] 17 Claims
 
1. An anhydrous crystalline compound having the structure of Formula (I),

OG Complex Work Unit Chemistry
mono-succinate salt.